ArriVent BioPharma, Inc. (AVBP): Net Income

Annual figures by period end, from SEC filings.

-$166.31M

Year ended 2025-12-31

-$163.74M

Trailing 12 months to 2026-06-30

2023-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$166.31M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$80.49M	n/m	2026-03-05, From 2024-01-01
2023-12-31	-$69.33M	n/a	2025-03-03, From 2023-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
ArriVent BioPharma, Inc. (AVBP)	2025-12-31	-$166.31M	n/m
Amylyx Pharmaceuticals, Inc. (AMLX)	2025-12-31	-$144.74M	n/m
Rocket Pharmaceuticals, Inc. (RCKT)	2025-12-31	-$223.12M	n/m
Keros Therapeutics, Inc. (KROS)	2025-12-31	$87.01M	n/m
Liquidia Corp (LQDA)	2025-12-31	-$68.92M	n/m
ARS Pharmaceuticals, Inc. (SPRY)	2025-12-31	-$171.30M	n/m
Prothena Corp Public Ltd Co (PRTA)	2025-12-31	-$244.09M	n/m
Lyell Immunopharma, Inc. (LYEL)	2025-12-31	-$274.45M	n/m
Sionna Therapeutics, Inc. (SION)	2025-12-31	-$75.27M	n/m

Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗